No Data
No Data
BioNTech Price Target Maintained With a $171.00/Share by Canaccord Genuity
BioNTech Is Maintained at Buy by Canaccord Genuity
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $150 Price Target
BioNTech Analyst Ratings
BioNTech's Strategic Acquisition of Biotheus Bolsters Oncology Portfolio and Justifies Buy Rating
funny Blobfish_5081 :
Abdelhakim B : thanks moomoo for today analyst rating release
104088143 : Home
104088143 : Good
Clement Lemons : okk
View more comments...